Vanguard Global Advisers’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
Other funds holding SPRY
Vanguard Global Advisers's SPRY Position: Q3 2026 in Review
Vanguard Global Advisers increased its ARS Pharmaceuticals (SPRY) stake by 1.2% in Q3 2026, buying an estimated $1.85K and bringing the position to 26,851 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #2703.
Vanguard Global Advisers first reported a position in SPRY in Q1 2026 and has held it in 3 quarters since. The position peaked at $213K in Q1 2026. 190 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.
- Vanguard Global Advisers held 26,851 shares of ARS Pharmaceuticals worth $116K as of Q3 2026.
- Vanguard Global Advisers bought 316 ARS Pharmaceuticals shares in Q3 2026, an estimated $1.85K.
- ARS Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2703 holding.
- Vanguard Global Advisers first reported a position in ARS Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's ARS Pharmaceuticals position peaked at $213K in Q1 2026.
- 190 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.